Hostname: page-component-848d4c4894-tn8tq Total loading time: 0 Render date: 2024-06-30T12:35:38.964Z Has data issue: false hasContentIssue false
  • English
  • Français

Characteristics and treatment patterns of children and adolescents with attention-deficit/hyperactivity disorder in real-world practice settings

Published online by Cambridge University Press:  23 March 2020

A. Joseph ,
K. Davis ,
M. Fridman ,
P. Gustafsson ,
J. Quintero ,
V. Sikirica  and
T. Banaschewski
A. Joseph
Affiliation:
Shire, Global HEOR and Epidemiology, Zug, Switzerland
K. Davis
Affiliation:
RTI Health Solutions, Health Economics, Research Triangle Park, USA
M. Fridman
Affiliation:
AMF Consulting Inc., Health Economics, Los Angeles, USA
P. Gustafsson*
Affiliation:
Linköping University, Department of Clinical and Experimental Medicine and Department of Child and Adolescent Psychiatry, Linköping, Sweden
J. Quintero
Affiliation:
Hosp. University Infanta Leonor, Psychiatry Department, Madrid, Spain
V. Sikirica
Affiliation:
Shire, Global HEOR and Epidemiology, Wayne, USA
T. Banaschewski
Affiliation:
Central Institute of Mental Health, Department of Child and Adolescent Psychiatry and Psychotherapy, Mannheim, Germany
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective

To document patient characteristics and treatment patterns in a real-world population diagnosed with attention-deficit/hyperactivity disorder (ADHD).

Methods

This was a retrospective chart review of children/adolescents (6–17 years) diagnosed with ADHD in the UK, Germany and Netherlands who initiated stimulant monotherapy (SM), non-stimulant (atomoxetine) monotherapy (NSM) or polypharmacy (SM/NSM ± SM/NSM or other psychotropics) on/after 1-1-2012. To facilitate descriptive comparisons, cohort quotas were imposed: ∼50% SM; ∼25% NSM; ∼25% polypharmacy. Index date was first SM, NSM or polypharmacy treatment on/after 1-1-2012. Patients were required to have ≥ 6 months’ pre-index (baseline) history and ≥ 12 months’ post-index follow-up. Analyses were descriptive.

Results

In total, 497 patients were included (mean [SD] age: 10.8 [2.9] years; 77% male); 65% (SM), 63% (NSM) and 83% (polypharmacy) had at least marked baseline ADHD severity based on Clinical Global Impressions scale (P < 0.05 SM/NSM vs polypharmacy). Ninety percent (SM), 75% (NSM) and 73% (polypharmacy) were pharmacotherapy naïve at index (all P < 0.10); 61% (SM), 65% (NSM) and 72% (polypharmacy) received previous behavioural therapy. In SM patients, methylphenidate was predominant (most frequent brands: Concerta® [29%], Medikinet® [28%]); in polypharmacy patients, methylphenidate plus atomoxetine (22%) or other psychotropic (19%) was most common. Index therapy switch was common, particularly in polypharmacy patients (25%) (P < 0.05 vs SM [14%] and NSM [13%]). Switches were precipitated by poor response in 75% of cases overall.

Conclusions

Polypharmacy patients generally presented a more complicated history (including higher ADHD severity) and treatment pathway versus monotherapy patients. Index therapy switches were commonplace and more frequent in polypharmacy patients, often due to poor response.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EW443
Information
European Psychiatry , Volume 33 , Issue S1: Abstracts of the 24th European Congress of Psychiatry , March 2016 , pp. s227
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.